Drug Detail

Information about Rogaratinib

Generic Name
 Rogaratinib
IND
 BAY 1163877
Brand Name (US)
Manufacturer
 Bayer
Drug Type
 Tyrosine Kinase Inhibitor
Delivery
 Oral
Approval Status
 Phase 2
Indications
 SDH Deficient GIST
Overall Strategy
 Pan-FGFR inhibitor
Strategy
 Block FGFR Pathway
Drug Category
 SDH-directed

Links

 

 Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models
   

Trials of this drug

  

 Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
   

Trial results

Search for this drug/combination in:

ClinicalTrials.gov

ASCO

Pubmed